TEL AVIV, Israel, Aug 28, 2026
BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on therapies for oncology and rare diseases, announced a definitive agreement for a $3.75 million financing through a registered direct offering and concurrent private placement. The transaction includes the purchase of 1,348,921 American Depositary Shares (ADSs), or ADS equivalents, at $2.78 per ADS, together with warrants to purchase up to 2,023,382 additional ADSs at the same exercise price. The financing is expected to close on or about August 31, 2026, subject to customary closing conditions. BioLineRx said it intends to use the net proceeds primarily to support research and development activities, working capital and general corporate purposes, providing additional funding as the company advances its clinical-stage pipeline.
BioLineRx Secures Funding for R&D Activities
Under the financing agreement, BioLineRx will issue 1,348,921 ADSs or ADS equivalents at $2.78 per ADS through the registered direct offering. Each ADS represents 600 ordinary shares of the company. In a concurrent private placement, investors will also receive warrants to purchase up to 2,023,382 ADSs, with the warrants carrying an exercise price of $2.78 per ADS and an expiration period of five years from issuance. The company expects gross proceeds of approximately $3.75 million before placement agent fees and other offering expenses. BioLineRx has indicated that the capital will support its ongoing drug research and development programs, while also providing resources for working capital and broader corporate requirements. Chardan is serving as the exclusive placement agent for the transaction.
Warrant Amendment Accompanies Financing
Alongside the new financing, BioLineRx entered into a warrant amendment on August 27, 2026, involving certain outstanding ordinary warrants previously issued to and held by the investor participating in the offering. Under the amendment, the affected warrants covering 277,273 ADSs will have a reduced exercise price of $2.78 per ADS and an extended expiration date through August 31, 2031. The new securities issued in the private placement and the unregistered warrants are being offered under applicable exemptions from U.S. securities registration requirements. BioLineRx stated that the securities underlying the private placement and warrants have not been registered under the U.S. Securities Act and may not be offered or sold in the United States except under an effective registration statement or an applicable exemption. The financing therefore provides the company with additional capital while also modifying certain existing warrant terms as part of the transaction.
Advertisement
Oncology Pipeline Remains Central to Strategy
The financing comes as BioLineRx continues advancing its clinical development portfolio in oncology and rare diseases. The company identifies GLIX1 as its lead development asset, describing it as a first-in-class, oral small molecule targeting the DNA damage response pathway in glioblastoma and other solid tumors. A Phase 1/2a clinical trial of GLIX1 was initiated during the first quarter of 2026 under a collaboration with Hemispherian AS. BioLineRx also retains development rights to motixafortide in metastatic pancreatic ductal adenocarcinoma (PDAC), where a Phase 2b clinical trial is ongoing under a collaboration with Columbia University. BioLineRx’s first approved product, APHEXDA® (motixafortide), is indicated in the United States for stem cell mobilization for autologous transplantation in multiple myeloma. Commercialization rights are held by Ayrmid Ltd. globally except Asia and by Gloria Biosciences in Asia, while BioLineRx continues to retain rights for development in metastatic pancreatic cancer. The company’s latest financing is therefore intended to support both its broader corporate operations and continued investment in its development programs as it progresses its pipeline.The $3.75 million financing represents an additional source of capital for BioLineRx as it advances clinical development of its oncology-focused candidates. While the transaction is primarily a corporate financing milestone rather than a clinical or regulatory development, the proceeds are expected to support activities associated with the company’s therapeutic pipeline and ongoing operations.
Source: BioLineRx press release
